GSK plc reported strong Q3 2025 earnings with sales of £8.5 billion (+8% year-over-year) and upgraded its full-year guidance, anticipating a turnover growth of 6-7%. Core operating profit is expected to rise by 9-11%, supported by significant growth in Specialty Medicines, Vaccines, and General Medicines.